Indian Pharma major Alembic Pharmaceuticals on Wednesday said its joint venture Aleor Dermaceuticals has received tentative approval from the United State health regulator for generic Testosterone Gel used for treating testosterone deficiency.

Alembic Pharmaceuticals said in a regulatory filing to the stock exchanges read:  Aleor Dermaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Testosterone Gel, 1.62 percent (20.25 mg/1.25 gm actuation), The product is a generic version of AbbVie Inc's AndroGel in the same strength, it added. According to IQVIA data, Testosterone Gel, 1.62 percent (20.25 mg/1.25 gm actuation) has an estimated market size of USD 107 million for twelve months ending September 2020, the filing said.

"The product is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism and hypogonadotropic hypogonadism," it added. The company has a cumulative total of 136 ANDA approvals (117 final approvals and 19 tentative approvals) from USFDA, Alembic Pharma said.

Reacting to the development, Shares of Alembic Pharmaceuticals reached an intraday high level of Rs 999.95 .90 per scrip on NSE on Wednesday's session and later cooled down. 

CPSE made Phenomenal procurement and payment to MSMEs

Tacrolimus capsules USP launches in US market by Lupin, stock rises

HDFC Bank Valuation beats Rs 8 Lakh Crore